LymphedemaV1, Main, Curation, bibRecord, 007330

Breast cancer (non-metastatic)

Identifieur interne : 007330 ( Main/Curation ); précédent : 007329; suivant : 007331

Breast cancer (non-metastatic)

Auteurs : Justin Stebbing ; Geoff Delaney ; Alistair Thompson

Source :

BMJ Clinical Evidence [ 1752-8526 ] ; 2007.

RBID : PMC:2943780

Abstract

Introduction

Breast cancer affects at least 1 in 10 women in the UK, but most present with primary operable disease, which has an 80% 5-year survival rate overall.

Methods and outcomes

We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions after breast-conserving surgery for ductal carcinoma in situ? What are the effects of treatments for primary operable breast cancer? What are the effects of interventions in locally advanced breast cancer (stage IIIB)? We searched: Medline, Embase, The Cochrane Library and other important databases up to February 2006 (BMJ Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Results

We found 79 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.

Conclusions

In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding chemotherapy (cyclophosphamide/methotrexate/ fluorouracil and/or anthracycline and/or taxane-based regimens), or hormonal treatment to radiotherapy; adjuvant treatments (aromatase inhibitors, adjuvant anthracycline regimens, tamoxifen); axillary clearance; axillary dissection plus sentinel node dissection; axillary radiotherapy; axillary sampling; combined chemotherapy plus tamoxifen; chemotherapy plus monoclonal antibody (trastuzumab); extensive surgery; high-dose chemotherapy; hormonal treatment; less extensive mastectomy; less than whole breast radiotherapy plus breast conserving surgery; multimodal treatment; ovarian ablation; primary chemotherapy; prolonged adjuvant combination chemotherapy; radiotherapy (after breast-conserving surgery, after mastectomy, plus tamoxifen after breast-conserving surgery, to the internal mammary chain, and to the ipsilateral supraclavicular fossa, and total nodal radiotherapy); sentinel node biopsy; and standard chemotherapy regimens.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2943780

PubMed: 19450345
PubMed Central: 2943780

Links toward previous steps (curation, corpus...)

to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004762
to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :004761
to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003B80
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :003411
to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :003411
to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003411
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :007476

Links to Exploration step

PMC:2943780

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Breast cancer (non-metastatic)</title>
<author><name sortKey="Stebbing, Justin" sort="Stebbing, Justin" uniqKey="Stebbing J" first="Justin" last="Stebbing">Justin Stebbing</name>
</author>
<author><name sortKey="Delaney, Geoff" sort="Delaney, Geoff" uniqKey="Delaney G" first="Geoff" last="Delaney">Geoff Delaney</name>
</author>
<author><name sortKey="Thompson, Alistair" sort="Thompson, Alistair" uniqKey="Thompson A" first="Alistair" last="Thompson">Alistair Thompson</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">19450345</idno>
<idno type="pmc">2943780</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2943780</idno>
<idno type="RBID">PMC:2943780</idno>
<date when="2007">2007</date>
<idno type="wicri:Area/Pmc/Corpus">004762</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">004762</idno>
<idno type="wicri:Area/Pmc/Curation">004761</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">004761</idno>
<idno type="wicri:Area/Pmc/Checkpoint">003B80</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003B80</idno>
<idno type="wicri:Area/Ncbi/Merge">003411</idno>
<idno type="wicri:Area/Ncbi/Curation">003411</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003411</idno>
<idno type="wicri:Area/Main/Merge">007476</idno>
<idno type="wicri:Area/Main/Curation">007330</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Breast cancer (non-metastatic)</title>
<author><name sortKey="Stebbing, Justin" sort="Stebbing, Justin" uniqKey="Stebbing J" first="Justin" last="Stebbing">Justin Stebbing</name>
</author>
<author><name sortKey="Delaney, Geoff" sort="Delaney, Geoff" uniqKey="Delaney G" first="Geoff" last="Delaney">Geoff Delaney</name>
</author>
<author><name sortKey="Thompson, Alistair" sort="Thompson, Alistair" uniqKey="Thompson A" first="Alistair" last="Thompson">Alistair Thompson</name>
</author>
</analytic>
<series><title level="j">BMJ Clinical Evidence</title>
<idno type="eISSN">1752-8526</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec><title>Introduction</title>
<p>Breast cancer affects at least 1 in 10 women in the UK, but most present with primary operable disease, which has an 80% 5-year survival rate overall.</p>
</sec>
<sec><title>Methods and outcomes</title>
<p>We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions after breast-conserving surgery for ductal carcinoma in situ? What are the effects of treatments for primary operable breast cancer? What are the effects of interventions in locally advanced breast cancer (stage IIIB)? We searched: Medline, Embase, The Cochrane Library and other important databases up to February 2006 (BMJ Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). </p>
</sec>
<sec><title>Results</title>
<p>We found 79 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.</p>
</sec>
<sec><title>Conclusions</title>
<p>In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding chemotherapy (cyclophosphamide/methotrexate/ fluorouracil and/or anthracycline and/or taxane-based regimens), or hormonal treatment to radiotherapy; adjuvant treatments (aromatase inhibitors, adjuvant anthracycline regimens, tamoxifen); axillary clearance; axillary dissection plus sentinel node dissection; axillary radiotherapy; axillary sampling; combined chemotherapy plus tamoxifen; chemotherapy plus monoclonal antibody (trastuzumab); extensive surgery; high-dose chemotherapy; hormonal treatment; less extensive mastectomy; less than whole breast radiotherapy plus breast conserving surgery; multimodal treatment; ovarian ablation; primary chemotherapy; prolonged adjuvant combination chemotherapy; radiotherapy (after breast-conserving surgery, after mastectomy, plus tamoxifen after breast-conserving surgery, to the internal mammary chain, and to the ipsilateral supraclavicular fossa, and total nodal radiotherapy); sentinel node biopsy; and standard chemotherapy regimens.</p>
</sec>
</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007330 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 007330 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     PMC:2943780
   |texte=   Breast cancer (non-metastatic)
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i   -Sk "pubmed:19450345" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Breast cancer (non-metastatic)

Breast cancer (non-metastatic)

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki